Market closedNon-fractional

Akero Therapeutics/AKRO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Akero Therapeutics

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Ticker

AKRO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

59

AKRO Metrics

BasicAdvanced
$1.9B
Market cap
-
P/E ratio
-$3.22
EPS
-0.31
Beta
-
Dividend rate
$1.9B
-0.31
30.116
29.864
4.222
4.222
-56.17%
-20.23%
-31.11%
2.19
2.19
-9.555
20.87%
8.88%

What the Analysts think about AKRO

Analyst Ratings

Majority rating from 10 analysts.
Buy

AKRO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$53M
-3.27%
Profit margin
0.00%
NaN%

AKRO Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.55%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.60
-$0.71
-$0.99
-$0.90
-
Expected
-$0.63
-$0.68
-$0.86
-$0.95
-$0.94
Surprise
-4.46%
4.22%
14.95%
-5.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Akero Therapeutics stock?

Akero Therapeutics (AKRO) has a market cap of $1.9B as of July 23, 2024.

What is the P/E ratio for Akero Therapeutics stock?

The price to earnings (P/E) ratio for Akero Therapeutics (AKRO) stock is 0 as of July 23, 2024.

Does Akero Therapeutics stock pay dividends?

No, Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Akero Therapeutics dividend payment date?

Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders.

What is the beta indicator for Akero Therapeutics?

Akero Therapeutics (AKRO) has a beta rating of -0.31. This means that it has an inverse relation to market volatility.

Buy or sell Akero Therapeutics stock

Buy or sell Akero Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing